Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Valentis moves IL-2 gene therapy to phase II

July 1, 1999

InKine files two patent applications relating to thrombospondin receptor

July 1, 1999

NCI initiates phase I trials with patient-specific cancer vaccines

July 1, 1999

Introgen Therapeutics receives milestone payment from RPR

July 1, 1999

Aronex reports responses in phase II trial of Atragen as treatment of NHL

June 30, 1999

New compounds from Merck inhibit posttranslational farnesylation of proteins

June 30, 1999

FeRx's targeted carrier tested in doxorubicin delivery to liver cancer patients

June 30, 1999

QLT terminates collaboration with Beaufour Ipsen

June 30, 1999

Continued focus at Merck on inhibitors of protein farnesyltransferase

June 29, 1999

Ligand submits NDA for Targretin capsules and reports positive interim data from psoriasis study

June 29, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 26, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
Dual-targeting, rapamycin-enhanced CAR T for multiple myeloma
BioWorld Science
Umoja Biopharma Inc. performed preclinical studies to evaluate the antitumor activity of UB-VV500, an off-the-shell lentiviral vector CAR T-cell product. It is...